Browsing by Subject "Lung non small cell cancer"

Article

Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: An EORTC-ECSG phase II clinical study

Gamucci, T.; Paridaens, R.; Heinrich, B.; Schellens, J. H. M.; Pavlidis, Nicholas; Verweij, J.; Sessa, Cristiana; Kaye, Stanley B.; Roelvink, M.; Wanders, J.; Hanauske, A. R. (2000)

Background: GI147211 is a water-soluble synthetic analogue of camptothecin showing promising in vivo and in vitro antitumor activity and an acceptable toxicity profile. Patients and methods: Between April 1995 and November ...

Article

Can circulated lung cancer cells pass to the urine without apparent urine tract metastases?. A single centre series

Kamposioras, K.; Pentheroudakis, George; Malamou-Mitsi, Vassiliki D.; Pappa, L.; Bafa, M.; Pavlidis, Nicholas (2008)

Urine cytology has been a useful tool for the diagnosis of urinary tract malignancies. However, the presence of tumor cells in the urine sediment without an obvious urothelial metastatic deposit is a rare phenomenon and ...

Article

Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Peccatori, Fedro A.; Azim, Hatem A.; Orecchia, R.; Hoekstra, H. J.; Pavlidis, Nicholas; Kesic, V.; Pentheroudakis, George (2013)

Article

Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A Hellenic Cooperative Oncology Group (HeCOG) phase II study

Kosmidis, Paraskevas A.; Fountzilas, George; Baka, S.; Samantas, E.; Dimopoulos, M. A.; Gogas, H.; Skarlos, Dimosthenis V.; Papacostas, P.; Boukovinas, I.; Bakoyiannis, Chris; Pantelakos, P.; Athanassiou, E.; Misailidou, D.; Tsekeris, P.; Pavlidis, Nicholas (2007)

Concurrent chemoradiotherapy has become a standard therapy for locoregionally advanced inoperable non-small cell lung cancer (NSCLC). The purpose of this phase II trial was to evaluate the efficacy and toxicity of concurrent ...

Article

Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: A phase III randomized study. Preliminary results

Kosmidis, Paraskevas A.; Mylonakis, N.; Dimopoulos, M. A.; Pavlidis, Nicholas; Fountzilas, George; Samantas, E.; Dimitriadis, K.; Kalofonos, H. P.; Tsavdaridis, D.; Skarlos, Dimosthenis V. (2000)

Gemcitabine plus paclitaxel and paclitaxel plus carboplatin are active and well tolerated in patients with advanced non-small cell lung cancer, showing similar rates of response and survival. The Hellenic Cooperative ...

Article

The diagnostic and therapeutic management of leptomeningeal carcinomatosis

Pavlidis, Nicholas (2004)

Article

Disseminated intravascular coagulation (DIC) and non-small cell lung cancer (NSCLC): Report of a case and review of the literature

Voulgaris, E.; Pentheroudakis, George; Vassou, A.; Pavlidis, Nicholas (2009)

The clinical manifestation of disseminated intravascular coagulation (DIC) as paraneoplastic phenomenon is common in patients with lung cancer (especially in those with non small cell lung cancer).Surprisingly, only few ...

Article

Docetaxel (Taxotere™) is active in non-small-cell lung cancer: A phase II trial of the EORTC early clinical trials group (ECTG)

Cerny, T.; Kaplan, S.; Pavlidis, Nicholas; Schöffski, P.; Epelbaum, R.; Meerbeek, J. van; Wanders, J.; Franklin, H. R.; Kaye, Stanley B. (1994)

In a multicentre trial of the EORTC ECTG we have treated 43 non-pretreated patients with advanced non-small-cell lung cancer (NSCLC) with the new semisynthetic taxoid docetaxel (Taxotere). Six patients were ineligible; of ...

Article

ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC)

Felip, E.; Stahel, R. A.; Pavlidis, Nicholas (2005)

Article

Intensified carboplatin regimen with GM-CSF support in non-small cell lung cancer (NSCLC). A Hellenic Co-operative Oncology Group study (HeCOG)

Nikolaides, C.; Klouvas, G. D.; Fountzilas, George; Athanasiades, A.; Skarlos, Dimosthenis V.; Samantas, E.; Kosmidis, Paraskevas A.; Mylonakis, N.; Pavlidis, Nicholas (1997)

This is a continuation of a HeCOG previous trial utilizing carboplatin and vindesine in conventional doses as a non-toxic regimen provided easily on an outpatient basis in NSCLC. In the present study we investigated whether ...

Article

Levels of absolute survival benefit for systemic therapies of advanced cancer: A call for standards

Ioannidis, J. P. A.; Pavlidis, Nicholas (2003)

Research on systemic interventions in patients with advanced stage malignancies should be systematised with an emphasis on the absolute gain in survival for the median patient. Such information is most meaningful with ...

Article

Lung cancer during pregnancy: An emerging issue

Pavlidis, Nicholas (2008)

Article

Lung cancer in pregnancy: Report of nine cases from an international collaborative study

Boussios, Stergios; Han, S. N.; Fruscio, R.; Halaska, M. J.; Ottevanger, P. B.; Peccatori, Fedro A.; Koubková, L.; Pavlidis, Nicholas; Amant, F. (2013)

Objective: Lung cancer is an uncommon diagnosis during pregnancy. The combination of smoking in young women, increased maternal age during pregnancy, and increasing incidence of lung cancer worldwide may cause an increase ...

Article

Lung cancer in the pregnant woman: To treat or not to treat, that is the question

Jr, H. A. Azim; Peccatori, Fedro A.; Pavlidis, Nicholas (2010)

Lung cancer in pregnancy is a rare situation; however, it is increasingly reported in the past two decades. The association might be more encountered in the coming years due to the rising trends of cigarette smoking among ...

Article

Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature review

Pentheroudakis, George; Greco, F. A.; Pavlidis, Nicholas (2009)

Background: Gene expression profiling platforms were recently shown to accurately assign cancer of unknown primary (CUP) to a primary tissue of origin, with unknown impact on patient outcome. We examined chemotherapy ...

Article

Multicentre phase II pharmacological evaluation of rhizoxin

McLeod, H. L.; Murray, L. S.; Wanders, J.; Setanoians, A.; Graham, M. A.; Pavlidis, Nicholas; Heinrich, B.; Huinink, W. W. Ten Bokkel; Wagener, D. J. Th; Aamdal, S.; Verweij, J. (1996)

Rhizoxin is a macrocyclic lactone compound that binds to tubulin and inhibits microtubule assembly. Rhizoxin demonstrated preclinical anti-tumour activity against a variety of human tumour cell lines and xenograft models. ...

Article

Non-small cell lung cancer in the young: A retrospective analysis of diagnosis, management and outcome data

Mauri, D.; Pentheroudakis, George; Bafaloukos, Dimitrios; Pectasides, Dimitrios; Samantas, E.; Efstathiou, E.; Kalofonos, H. P.; Syrigos, K.; Klouvas, G. D.; Papakostas, P.; Kosmidis, Paraskevas A.; Fountzilas, George; Pavlidis, Nicholas (2006)

Background: Non-small cell lung cancer (NSCLC) in young patients is uncommon and is thought to constitute a distinct oncological entity with characteristic clinicopathological patterns. Since the reported data are scant ...

Article

Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial

Kosmidis, Paraskevas A.; Mylonakis, N.; Skarlos, Dimosthenis V.; Samantas, E.; Dimopoulos, M. A.; Papadimitriou, C.; Kalofonos, H. P.; Pavlidis, Nicholas; Nikolaides, C.; Papaconstantinou, C.; Fountzilas, George (2000)

Purpose: The combination of paclitaxel and carboplatin has become a widely used regimen in NSCLC due to phase II reports of moderate toxicity, reasonable activity and easy outpatient administration. Purpose of our present ...

Article

Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: A randomized study

Kosmidis, Paraskevas A.; Mylonakis, N.; Fountzilas, George; Samantas, E.; Athanasiades, A.; Pavlidis, Nicholas; Skarlos, Dimosthenis V. (1997)

A recent phase II study by our group documented a response rate of 27% with the combination paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 plus carboplatin dosed to a target area under the ...

Article

Paclitaxel (175 mg/m2) plus carboplatin versus paclitaxel (225 mg/m2) plus carboplatin in non-small cell lung cancer: a randomized study.

Kosmidis, Paraskevas A.; Mylonakis, N.; Fountzilas, George; Samantas, E.; Athanasiades, A.; Pavlidis, Nicholas; Skarlos, Dimosthenis V. (1997)

A recent phase II study by our group documented a response rate of 27% with the combination paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 plus carboplatin dosed to a target area under the ...